Rheumatology

Research Focuses on Etanercept Biosimilar SB4, Treatment Retention, and Disease Activity

October 18th 2018

By Samantha DiGrande

As biosimilar etanercept SB4, sold in many markets as Benepali, has entered the rheumatoid arthritis treatment space, researchers have recognized the need to investigate the retention rates and disease activity scores among patients receiving SB4 and its reference.

Despite Educational Efforts, Providers Still Lack Knowledge on Biosimilars

October 18th 2018

By Kelly Davio

Article

Stakeholders hoping to see increased uptake of biosimilars in the United States are increasingly pointing to a lack of provider awareness as a key hindrance to the biosimilars marketplace. New research, to be presented at the American College of Rheumatology Annual Meeting in Chicago, Illinois, held from October 19-24, 2018, suggests that, despite efforts to educate providers, awareness of biosimilars—as well as awareness of patients’ attitudes toward them—remains low.

Third Biosimilar Adalimumab, Imraldi, Enters Europe

October 17th 2018

By Kelly Davio

Article

One day after Sandoz and Amgen announced European launches of their biosimilar adalimumab products referencing Humira, Samsung Bioepis announced that it has launched its own biosimilar, Imraldi.

Lessons Learned From Nonmedical Switching

October 16th 2018

By Kelly Davio

Article

As more biosimilars are poised to become available to US patients, American rheumatologists are looking to their European counterparts for lessons learned from nonmedical switches from reference products to biosimilars. During the American College of Rheumatology (ACR) Annual Meeting in Chicago, Illinois, held from October 19-24, 2018, several research teams will present on nonmedical switching in the European context.

Europe Sees Its First Adalimumab Biosimilar Launches

October 16th 2018

By The Center for Biosimilars Staff

Article

Sandoz has announced that its biosimilar adalimumab, Hyrimoz, became available today in the United Kingdom, and Amgen announced that it will begin making its Amgevita available in multiple European markets.

Review Finds Better Efficacy of Biologics in Trials Without Placebo

October 15th 2018

By Samantha DiGrande

Article

A review was recently conducted among 2 different types of randomized clinical trials in the treatment of rheumatoid arthritis (RA): those comparing reference biologics’ efficacy versus placebo, and those comparing reference biologics’ efficacy versus biosimilars.

Real-World Data Show Mixed Results for CT-P13 Worldwide

October 15th 2018

By Kelly Davio

Article

During the American College of Rheumatology 2018 annual meeting, which will be held from October 19-24 in Chicago, Illinois, a variety of researchers will present on real-world data concerning biosimilar infliximab CT-P13.

European Analysis Finds Infliximab to Be Most Cost-Effective Biologic for RA

October 11th 2018

By The Center for Biosimilars Staff

Article

The paper reports findings from a study that used retrospective data from a single center in Poland from 2009 to 2014. Records from a total of 104 patients, each of whom received infliximab, etanercept, or adalimumab under the National Health Fund, were assessed.

NHS Releases Patient Education Materials in Preparation for Biosimilar Adalimumab

September 25th 2018

By Samantha DiGrande

Article

The National Health Service’s (NHS) Specialist Pharmacy Service released resources for clinicians to use with patients in the discussions around switching from the reference Humira to a biosimilar.

Switching to Biosimilars in Rheumatological Indications Is Safe, Review Says

September 25th 2018

By Kelly Davio

Article

The latest review seeking to reassure clinicians about the safety of switching their patients to biosimilars focuses on rheumatology indications.